<DOC>
	<DOCNO>NCT01501669</DOCNO>
	<brief_summary>This study multicenter , randomize study , open-label , phase III study.The efficacy irinotecan capecitabine combination superior capecitabine alone term progression free survival metastatic breast cancer patient previously treat anthracycline taxane .</brief_summary>
	<brief_title>Irinotecan/Capecitabine Versus Capecitabine Patients Treated With A/T HER2 Negative Metastatic Breast Cancer</brief_title>
	<detailed_description>Prior enrollment , patient confirm hormone HER2 receptor status . Patients may either measurable and/or evaluable metastatic lesion able assessed chest , abdomen CT bone scan perform within 28 day prior start treatment . - Capecitabine alone arm : 1250 mg/m2 , BID , day 1-14 , every 3 week - Irinotecan plus capecitabine arm : Irinotecan 80 mg/m2 , day 1 8 , every 3 week + capecitabine 1000 mg/m2 , BID , day 1-14 , every 3 week . Randomization do use random block size permutation method stratify base : hormone receptor status ( negative vs. positive ) , first line vs. second line , visceral metastasis ( negative vs. positive ) . Treatment continue disease progression , death , discontinuation due side effect drug refusal patient . The primary objective study estimate PFS capecitabine irinotecan patient anthracycline taxane- pretreated metastatic breast cancer , estimate Kaplan-Meier method compare log-rank test . Overall survival also estimate method . The secondary statistical analysis consist estimation complete partial response rate response rate treatment calculate ratio number complete partial responder total number evaluable patient toxicity profile , estimate ratio number occurrence total number evaluable patient . A 95 % confidence interval response rate compute base binomial distribution function . The analysis report final treatment result undertaken patient potentially follow minimum 12 month . The overall survival progression free survival , respective median estimate 95 % confidence interval .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Histologically confirm stage IV recurrent breast cancer HER2 negative disease , HER2 unknown disease eligible antiHER2 therapy ECOG performance status 02 Age ≥ 20 year Patients receive anthracycline base chemotherapy ( neo ) adjuvant metastatic setting experience disease progression taxane base chemotherapy metastatic setting , patient experience disease recurrence within 1 year completion ( neo ) adjuvant anthracycline taxane base chemotherapy In case patient treat capecitabine adjuvant setting , disease recurrence occur within 1 year completion capecitabine chemotherapy Patients brain metastasis enrol n't need treatment regard brain metastasis Previous chemotherapy radiotherapy complete least 3 week randomization Measurable evaluable disease accord Response Evaluation Criteria Solid Tumors ( RECIST ) version 1.1 [ 21 ] Adequate hematopoietic function : absolute granulocyte count ≥ 1,500/mm3 , platelet ≥ 100,000/mm3 , hemoglobin ≥ 10g/mm3 Adequate hepatic function : total bilirubin ≤ 1.5mg/dL , alkaline phosphatase ( ALP ) ≤ 2.5 x UNL , AST/ALT ≤ 2x UNL , liver function abnormality due underlying malignancy exists , AST/ALT ≤ 2.5 x UNL , total bilirubin ≤ 3.0mg/dL , ( ALP ) ≤ 5 x UNL case bone metastasis ; ALP ≤ 5 x UNL Adequate renal function : serum creatinine ≤ 1.5mg/dL Ability understand comply protocol study period Patients sign write informed consent study entry Pregnant lactate woman Patients receive irinotecan capecitabine metastatic breast cancer treatment Patients HER2 positive breast cancer Grade 2 great peripheral neuropathy Patients symptomatic brain metastasis Prior unanticipated severe reaction fluropyrimidine therapy know sensitivity 5fluorouracil Patients history cancer situ cervical cancer nonmelanotic skin cancer Patients GI tract disease result inability take oral medication , malabsorption syndrome , requirement IV alimentation , prior surgical procedure affect absorption , uncontrolled GI disease ( e.g . Crohn 's disease , ulcerative colitis )</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>irinotecan</keyword>
	<keyword>capecitabine</keyword>
	<keyword>metastatic breast cancer</keyword>
</DOC>